KALA News and Press, Kala Pharmaceuticals Inc. From 01/15/20

Kala Pharmaceuticals (NASDAQ: KALA ) has completed enrollment of ~900 patients in its STRIDE 3 (Short Term Relief In Dry Eye) Phase 3 clinical trial for KPI-121 0.25%, for the short-term treatment of dry eye disease. More news on: Kala Pharmaceuticals, Inc., Healthcare stocks news, ...

–STRIDE 3 Topline Data Targeted in First Quarter of 2020– Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) ...

Oyster Point Pharma ( OYST +4.6% ) is up on average volume in response to positive topline results from a Phase 2 clinical trial, MYSTIC , evaluating lead candidate OC-01 nasal spray for the treatment of dry eye disease. More news on: Oyster Point Pharma, Inc., Kala Pharmaceuticals,...

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that it will present at the 38 th Annual J....

Kala Pharmaceuticals ( KALA ) is based in the Boston area, Massachusetts, and is focused on developing topical treatments for eye diseases using its proprietary MPP (Mucus Penetrating Particles) technology. Topically administered eye medications are usually trapped by the mucus in the tear fil...

Gainers:  aTyr Pharma (NASDAQ: LIFE )  +48% . More news on: aTyr Pharma, Inc., Mechel PAO, The Habit Restaurants, Inc., Stocks on the move, Read more ...

aTyr Pharma (NASDAQ: LIFE ) +63%  on Kyorin Pharma deal . More news on: aTyr Pharma, Inc., Town Sports International Holdings, Inc., Pulmatrix, Inc., Stocks on the move, Read more ...

Amgen (NASDAQ: AMGN ) resumed with Overweight rating and $280 (15% upside) price target at Morgan Stanley. More news on: Amgen Inc., Hill-Rom Holdings, Inc., Johnson & Johnson, Healthcare stocks news, Stocks on the move, , Read more ...

The following slide deck was published by Kala Pharmaceuticals, Inc. in conjunction with this Read more ...

Kala Pharmaceuticals, Inc. (KALA) Q3 2019 Earnings Conference Call November 07, 2019 08:00 AM ET Company Participants Niranjan Kameswaran - Vice President, Strategy Mary Reumuth - Chief Financial Officer Mark Iwicki - Chairman, President & Chief Executive Officer Kim Brazze...